on The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has filed Form 8.3 regarding its position in Avadel Pharmaceuticals plc. As of December 11, 2025, Vanguard holds a 5.74% interest in Avadel's US$0.01 ordinary shares, totaling 5,595,511 securities. This disclosure is in accordance with Rule 8.3 of the Irish Takeover Panel Act, 1997.
Recent transactions include a purchase of 3,625 shares and a sale of 2,108 shares, both at a price of 21.39 USD per unit. No cash-settled or stock-settled derivative transactions were reported. Additionally, there are no indemnity or option arrangements or agreements relating to voting rights or future acquisitions.
The disclosure confirms that Vanguard is not acting in concert with any other parties concerning Avadel. No supplemental information was appended to this filing.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news